G1’s product revenue guidance is based on expectations for continued acceleration of sales performance of COSELA in the U.S. Additionally, the Company believes that its current cash runway is sufficient to fund its operations into 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GTHX:
- G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
- G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
- Is GTHX a Buy, Before Earnings?
- Biotech Alert: Searches spiking for these stocks today
- G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024
